Physician profile
Darell T Covington
NPI 1134128622
$4,124.05
in general payments reported to CMS, 2019-2025
17 companies · $921 in 2025
The $921 reported for 2025 was more than what a typical Colon & Rectal Surgery provider received nationally (typical 2025 total: $317).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $380 · 2020: $270 · 2021: $236 · 2022: $785 · 2023: $574 · 2024: $957 · 2025: $921.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,453.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,452.98 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $817.10 | 2019-2025 | Rinvoq, Linzess |
| Janssen Biotech, INC. | $782.43 | 2019-2025 | Tremfya, Stelara, Simponi |
| Celgene Corporation | $525.14 | 2021-2024 | Zeposia |
| Braintree Laboratories, INC. | $379.70 | 2019-2023 | Sutab, Suflave |
| Takeda Pharmaceuticals U.S.A., INC. | $262.96 | 2023-2025 | Entyvio, Gattex |
| Exact Sciences Corporation | $250.79 | 2023-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Pfizer INC. | $233.86 | 2019-2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $231.75 | 2019-2025 | Xifaxan |
| Ferring Pharmaceuticals INC. | $153.57 | 2019-2024 | Rebyota |
| Madrigal Pharmaceuticals | $147.01 | 2025 | Rezdiffra |
| Phathom Pharmaceuticals, INC. | $81.70 | 2023-2025 | Voquezna |
| Aimmune Therapeutics, INC. | $58.60 | 2024-2025 | Zenpep |
| Lilly USA, LLC | $58.33 | 2024 | Omvoh |
| Novo Nordisk INC | $48.70 | 2025 | Wegovy |
| Axonics, INC. | $39.64 | 2022-2023 | Axonics |
Show all 17 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ardelyx, INC. | $32.38 | 2024 | Ibsrela |
| Intercept Pharmaceuticals, INC. | $20.39 | 2024 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Darell Covington listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.